STOCKHOLM, April 23 /PRNewswire/ -- Pharmalink AB today announced that it has strengthened its Board of Directors as the company's portfolio continues to move towards late stage product development and commercialization. Two highly experienced pharmaceutical and biotechnology advisors, Anders Wiklund and Jens Christensen, are joining the Board. In addition, Lennart Hansson, Director of the lifesciences business area at Industrifonden joins the Board as the Industrifonden representative.
Lennart Hansson, PhD, has a broad experience in the life science sector having worked in leading and executive positions at KabiGen, Symbicom, AstraZeneca, Arexis, Biovitrum and Karolinska Development. Dr Hansson replaces retiring Board member Professor Jorgen Lonngren. Industrifonden is an independent foundation founded by the Swedish state in 1979 and which operates on a commercial basis without outside capital. Revenues are returned to new investments. Industrifonden was an early investor in Pharmalink and holds around 15% the Company.
Mr Anders Wiklund, MPharm, has been an advisor to the biotechnology industry since 1997 when he founded Wiklund International Inc. Previously, Mr Wiklund spent 29 years with the Pharmacia Group of companies in a number of executive positions, ultimately serving as President of Pharmacia Development Corp and Vice President of Pharmacia Upjohn, working in the US. In his advisory role, Mr Wiklund has worked with companies in the US, Canada and Scandinavia, and he was also a co-founder of Esperion Therapeutics Inc. Presently Mr Wiklund serves on the board of QuatRx Inc, Gyros AB, and EffRx Inc, where he also is President. Mr Wiklund replaces retiring Non-Executive Board member Mr Anders Lonner.
Jens Kristensen, MD, PhD, is VP of Clinical Development at KaroBio AB, a
public Swedish drug development company. As a specialist in
anaesthesiology/intensive care and in pharmaceutical
|SOURCE Pharmalink AB|
Copyright©2009 PR Newswire.
All rights reserved